Vineet Laboratories Share Price & Earnings Call Analysis

Financials of Vineet Laborator

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Vineet Laborator

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +37.55%37.50%37.50%36.07%35.85%35.85%29.26%15.89%12.46%5.98%5.98%5.98%
FIIs +0.24%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.36%0.50%0.24%
Public +62.20%62.50%62.49%63.93%64.15%64.15%70.74%84.11%87.54%93.67%93.52%93.78%
No. of Shareholders9,5149,6389,52310,30010,05810,0259,9889,68210,0039,9299,9019,724

Pros & Cons

Vineet Laborator

Key positives and risks surfaced from the company insights section.

Pros
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -24.6% over past five years.
  • Promoter holding is low: 5.98%
  • Company has a low return on equity of -22.7% over last 3 years.
  • Promoter holding has decreased over last 3 years: -32.7%
  • Working capital days have increased from 26.7 days to 89.0 days
Cons
No explicit risk notes available.
Raw Insights
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -24.6% over past five years.
  • Promoter holding is low: 5.98%
  • Company has a low return on equity of -22.7% over last 3 years.
  • Promoter holding has decreased over last 3 years: -32.7%
  • Working capital days have increased from 26.7 days to 89.0 days

Financials of Vineet Laborator

Quarterly Results

Quarter-by-quarter operating performance

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales +37.5243.3732.6537.0523.8618.9618.1014.087.4417.4215.6518.8910.39
Expenses +37.2639.2033.2933.6324.6519.2722.2325.127.1314.2413.1716.408.14
Operating Profit0.264.17-0.643.42-0.79-0.31-4.13-11.040.313.182.482.492.25
OPM %0.69%9.61%-1.96%9.23%-3.31%-1.64%-22.82%-78.41%4.17%18.25%15.85%13.18%21.66%
Other Income +0.030.010.010.410.370.200.031.380.020.010.050.030.11
Interest0.961.021.081.721.140.990.950.900.612.191.090.990.97
Depreciation0.610.610.630.670.610.620.620.660.630.630.630.540.60
Profit before tax-1.282.55-2.341.44-2.17-1.72-5.67-11.22-0.910.370.810.990.79
Tax %-2.34%4.71%-11.11%-34.03%-1.84%6.98%0.53%-6.24%-4.40%-8.11%-3.70%27.27%-92.41%
Net Profit +-1.252.42-2.071.92-2.13-1.83-5.71-10.53-0.870.400.850.731.51
EPS in Rs-0.651.26-1.081.00-1.11-0.95-2.97-5.48-0.450.210.440.380.79

Financials of Vineet Laborator

Profit & Loss

Annual income statement trend

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +0.00243.48191.10212.29150.5975.0059.4062.35
Expenses +0.01235.33177.94204.63143.3991.2850.9151.95
Operating Profit-0.018.1513.167.667.20-16.288.4910.40
OPM %3.35%6.89%3.61%4.78%-21.71%14.29%16.68%
Other Income +0.000.390.290.120.461.990.100.20
Interest0.002.672.093.384.783.984.895.24
Depreciation0.001.812.022.372.522.502.412.40
Profit before tax-0.014.069.342.030.36-20.771.292.96
Tax %0.00%56.16%28.91%38.42%-183.33%-2.79%13.18%
Net Profit +-0.011.786.641.251.03-20.191.113.49
EPS in Rs-0.110.933.460.650.54-10.520.581.82
Dividend Payout %0.00%0.00%13.89%0.00%0.00%0.00%0.00%

Financials of Vineet Laborator

Balance Sheet

Capital structure and asset base

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital0.419.229.229.229.229.2219.21
Reserves-0.0117.4024.0024.4625.515.4326.40
Borrowings +0.0012.4826.5131.0944.3040.0545.33
Other Liabilities +0.0069.6473.5951.0837.8439.8433.84
Total Liabilities0.40108.74133.32115.85116.8794.54124.78
Fixed Assets +0.0019.6721.3826.6526.9225.4624.24
CWIP0.000.000.000.000.000.000.00
Investments0.000.120.140.130.180.210.19
Other Assets +0.4088.95111.8089.0789.7768.87100.35
Total Assets0.40108.74133.32115.85116.8794.54124.78

Financials of Vineet Laborator

Cash Flows

Operating, investing and financing cash movement

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +0.0027.497.63-9.62-6.6111.49-12.03
Cash from Investing Activity +0.00-7.81-3.68-6.69-2.22-3.18-1.11
Cash from Financing Activity +0.0018.6211.960.278.43-8.2329.74
Net Cash Flow0.0038.3015.91-16.03-0.400.0816.60
Free Cash Flow0.0027.497.63-17.25-9.4010.44-13.23
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit0%327%82%-87%-88%-71%-144%

Financials of Vineet Laborator

Ratios

Working capital efficiency and return ratios

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days64.0369.1460.4576.5964.4870.05
Inventory Days73.12109.1997.79158.26259.67606.03
Days Payable114.08161.2073.90103.37174.65239.52
Cash Conversion Cycle23.0717.1384.34131.48149.50436.56
Working Capital Days14.41-19.4620.6328.48-37.2888.98
ROCE %34.08%23.13%8.69%6.65%-27.95%8.49%

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Venus Remedies Ltd (Q2 FY27)

    219.27 crores compared to Rs. Key results statement takeaways from Venus Remedies Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • ERIS Lifescience (Q2 FY27)

    Q2 FY27 Revenue: ₹892 crore, a 12.6% year-on-year (YoY) growth (Page 13,14) . Key investor presentation takeaways from ERIS Lifescience's Q2 FY27 investor prese

  • Sat Kartar Life Ltd (Q2 FY27)

    This represents a year-on-year revenue increase of approximately 26.43% [(11,387.49 . Key investor presentation takeaways from Sat Kartar Life Ltd's Q2 FY27 inv

  • Sakar Healthcare Ltd (Q2 FY27)

    Q2 FY27 revenue from operations: INR 8,741.61 Lakhs, up 52% YoY from INR 5,756.04 Lakhs in Q2 FY26 (Page 7). Key investor presentation takeaways from Sakar Heal

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Zydus Lifesci.